Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Contraception
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Contraception
    TopAbstracts in Contraception 11/17/2009 - (DGNews)
    Oral Contraceptives May Benefit Women With Asthma - (DGNews)
    Migraine and cardiovascular disease: systematic review and meta-analysis - (BMJ)
    TopAbstracts in Contraception 10/20/2009 - (DGNews)
    FDA Approves Levonorgestrel IUD to Treat Heavy Menstrual Bleeding - (DGNews)

    News archive

     Recent webcasts/CME - Contraception
      Pregnancy Planning and Preconception Health Care for HIV-Infected Individuals and Couples
      Improving Contraceptive Success: Facilitating Choice of Appropriate and Acceptable Contraceptive Methods
      Sterilization Methods for Women
      Gynecologic and Colorectal Cancer: Risks and Benefits of Contraceptive Methods
      Injectable Contraceptives

      Webcasts/CME archive

       Recent cases - Contraception
        Spontaneous Perforated Pyometra with an Intrauterine Device in Menopause: a Case Report
        Foreign Body Granuloma in the Anterior Abdominal Wall Mimicking an Acute Appendicular Lump and Induced by a Translocated Copper-T Intrauterine Contraceptive Device: A Case Report
        Co-Existence of a Giant Splenic Hemangioma and Multiple Hepatic Hemangiomas and the Potential Association With the Use of Oral Contraceptives: A Case Report
        Pelvic Actinomycosis Presenting with a Large Abscess and Bowel Stenosis with Marked Response to Conservative Treatment: A Case Report
        The Sexually Active Adolescent Who is Uncertain about Using Contraception

        Cases archive
          




        my personal edition > contraception > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Innovative Long-Acting Contraceptive Product Mirena(R) Approved in Japan

        BERLIN, GERMANY -- January 30, 2007 -- The Japanese Ministry of Health, Labour and Welfare (MHLW), has granted marketing approval for Bayer Schering Pharma's long-acting intrauterine contraceptive system Mirena®.

        The product is expected to be launched in Japan in April 2007 under the trade name Mirena® 52 mg and will significantly enhance the choice of methods of contraception available to women in Japan.

        "In Japan there has been a limited choice in convenient, reliable and reversible long-acting contraception" said Phil Smits, Head of Women's Healthcare at Bayer Schering Pharma AG. "We are delighted that with Mirena® we can offer women in Japan an innovative long-acting method for contraception. With the Mirena® launch in Japan we will further strengthen our leading position on the Japanese market and grow our worldwide leadership in female contraception".

        The approval is based on broad experience from international studies as well as a Japanese study program, including a large clinical trial with more than 400 Japanese women. Until now, Mirena® has been used by more than 10 million women worldwide and is registered in more than 100 countries. With the approval in Japan, Mirena® is now available in all major pharmaceutical markets worldwide.

        About Mirena®
        Mirena®, a levonorgestrel-releasing intrauterine contraceptive system (IUS), is marketed in many countries throughout the world. Mirena® offers advantages to other birth control options, in particular compared to conventional intrauterine devices (IUDs). In addition to preventing pregnancy effectively over a period of five years, many women experience shorter, lighter and less painful periods while using Mirena®. Mirena® does not contain estrogen. Instead, Mirena® delivers a low dose of the progestin levonorgestrel (approx. 20 microgram/day) to the lining of the uterus and thereby provides desired local effects and minimizes undesired systemic effects. The insertion and removal of the intrauterine system Mirena® takes only a few minutes. It can easily be done by a trained health care professional in a doctor's office on an outpatient basis. Once Mirena® is removed, fertility is rapidly restored.


        SOURCE: Bayer Health Care



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send